期刊文献+

两种化疗方案对晚期宫颈癌的疗效观察 被引量:2

Clinical effects of two chemotherapy regimens on advanced cervical cancer
下载PDF
导出
摘要 目的探究顺铂分别与多西它赛和紫杉醇联合对晚期宫颈癌的临床疗效。方法选取我院收治的80例局部晚期宫颈癌患者,采取随机数字表法将其分成A、B组,每组40例。A组患者采用多西它赛75mg/m2+顺铂50 mg/m2,B组患者采用紫杉醇60 mg/m2+顺铂50 mg/m2,分别化疗l^2个疗程,化疗间隔时间均为21 d,观察与比较2组患者经不同治疗方法后的临床疗效及不良反应等情况。结果 A、B组患者经不同用药方式后,疗效差异无统计学意义(P>0.05)。B组患者出现不良反应的例数明显高于A组患者,差异有统计学意义(P<0.05)。结论多西它赛75 mg/m2联合顺铂50 mg/m2对晚期宫颈癌临床作用显著,且不良反应较少,安全性高。 Objective To investigate the clinical effects of Cisplatin combined with Docetaxel versus Cy-clophosphamide on advanced cervical cancer. Methods Eighty patients with locally advanced cervical cancer hospi-talized in our hospital were included as the subjects in the study, and were divided into groups A and B randomly ( n=40 each). Group A received Docetaxel 75 mg/m2 and Cisplatin 50 mg/m2, while group B received Paclitaxel 60 mg/m2 and Cisplatin 50 mg/m2, with 1 to 2 courses of chemotherapies and an interval of 21 d. The clinical effects and ad-verse reactions of the two chemotherapies were determined and compared between the two groups of patients. Results There was no statistically significant difference in the effect between groups A and B after received different medica-tion (P〉0.05). The number of patients with adverse reactions in group B was significantly higher than that in group A, with statistically significant difference (P〈0.05). Conclusion Docetaxel 75 mg/m2 and Cisplatin 50 mg/m2 have sig-nificantly clinical effects on advanced cervical cancer, with less adverse reactions and high safety.
出处 《中国药物与临床》 CAS 2015年第9期1232-1233,共2页 Chinese Remedies & Clinics
基金 山西省卫生厅科研基金(201201008)
关键词 抗肿瘤联合化疗方案 宫颈肿瘤 治疗结果 Antineoplastic combined chemotherapy protocols Cervix neoplasms Treatment outcome
  • 相关文献

参考文献4

二级参考文献35

  • 1王赞宏,彭芝兰,段振玲,刘辉.自噬基因Beclin 1在宫颈鳞癌中的蛋白表达及其临床意义[J].四川大学学报(医学版),2006,37(6):860-863. 被引量:17
  • 2Ten Tije A J, Verweij J, Loos WJ, et al. Pharmacological efects of formulation vehicles : Implications for cancer chemotherapy [J]. Clin Pharmacokinet, 2003, 42 (7):665.
  • 3Weiss RB, Donehower RC, Wiemik PH, et al. Hypemensitivity reactions from taxol [ J ]. J Clin Oncol, 1990, 8 (7): 1263.
  • 4Yang T, Cui FD, Choi MK, et al. Liposome formulation of paclitaxel with enhanced solubility and stability [ J ]. Drug Delivery, 2007, 14:301.
  • 5Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophorw EL free liposome- based paclitaxel ( LEP-ETU ) formulation [ J ]. Eur J Pharm Biopharm, 2005, 59 : 177.
  • 6Weiss RB,Donehower RC,Wiemik PH,et 81. Hypersensitivity reactions from Taxol[J]. J Clin 0nco1,1990,8(7):1263.
  • 7Janice SK,Laurie E, Maxtha F,et al. A comparison of two prophylactic regimens f~ hypersensitivity rectloas to plitaxel[J]. Gynecol Oncol, 2002,84(3) :420.
  • 8Rosenbe P, Anderssan H, Boman K, et al.Pmndmnized uial slrle agent pataxel given week versus every three weeks and with peroral venus intravermus steroid premcation to patiertts with ovariml cance~ previously treated with plafimnn[J]. Aeta Oneologiea, 2002,41 (5): 418.
  • 9Kwon JS, Elit L, Finn M, et al. A cen d two prophylactic regi- mens for hypersensitivity reactions to paclltaxel [ J ]. Gynecol Oncol, 2002,84(3):420.
  • 10Cnnm-i A, Salvadm'i B, Tognonl A, et al. Rapid intravenous premediea- tion with dexamedmsone prevcvts hypersensitivity reactions to paclitaxvl [J]. Ann O,md,1996(9):978.

共引文献36

同被引文献20

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部